Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
AstraZeneca
ClinicalTrials.gov Identifier:
NCT01144338
First received: June 10, 2010
Last updated: January 5, 2016
Last verified: January 2016